Subject: Xgeva and Biosimilars SGM 2152-A P2025a

Drug

Xgeva and Biosimilars

XGEVA  (denosumab)

AUKELSO  (denosumab-kyqq)

BILPREVDA  (denosumab-nxxp)

BOMYNTRA  (denosumab-bnht)

JUBEREQ  (denosumab-desu)

OSENVELT  (denosumab-bmwo)

OZILTUS  (denosumab-mobz)

WYOST  (denosumab-bbdz)

XBRYK  (denosumab-dssb)

XTRENBO  (denosumab-qbde)

Policy:

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications^1-10

• Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors
• Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
• Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

Compendial Uses¹¹

• Second-line therapy for osteopenia/osteoporosis in patients with systemic mastocytosis
• Thyroid cancer as palliative care for bone metastases

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Multiple Myeloma^1-11

Authorization of 12 months may be granted for prevention of skeletal-related events in members with multiple myeloma.

Bone Metastases From a Solid Tumor^1-11

Authorization of 12 months may be granted for either of the following:

• For prevention of skeletal-related events in members with bone metastases from a solid tumor (e.g., breast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer)
• As palliative care for bone metastases from thyroid carcinoma

Giant Cell Tumor of Bone^1-11

Authorization of 12 months may be granted for treatment of giant cell tumor of bone.

Hypercalcemia of Malignancy^1-10,12-13

Authorization of 2 months may be granted for treatment of hypercalcemia of malignancy that is refractory to intravenous (IV) bisphosphonate therapy OR there is a clinical reason to avoid IV bisphosphonate therapy (e.g., history of intolerance or hypersensitivity to an IV bisphosphonate).

Systemic Mastocytosis¹¹

Authorization of 12 months may be granted for second-line therapy for osteopenia or osteoporosis in members with systemic mastocytosis that have not responded to therapy with bisphosphonates or who are not candidates for bisphosphonates because of renal insufficiency.

Continuation of Therapy

Hypercalcemia of Malignancy

Authorization of 2 months may be granted for continued treatment in members requesting reauthorization for hypercalcemia of malignancy who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

All Other Indications

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

Place of Service:

Outpatient

The above policy is based on the following references:

1. Xgeva [package insert]. Thousand Oaks, CA: Amgen Inc.; May 2025.
2. Aukelso [package insert]. Cambridge, MA: Biocon Biologics Inc.; September 2025.
3. Bilprevda [package insert]. Jersey City, NJ: Organon LLC; August 2025.
4. Bomyntra [package insert]. Lake Zurich, IL: Fresenius Kabi USA, LLC; March 2025.
5. Jubereq [package insert]. Raleigh, NC; Accord BioPharma Inc.; October 2025.
6. Osenvelt [package insert]. Jersey City, NJ: Celltrion USA, Inc.; September 2025..
7. Oziltus [package insert]. Piscataway, NJ: Amneal Pharmaceuticals LLC; October 2025.
8. Wyost [package insert]. Princeton, NJ: Sandoz Inc.; October 2024.
9. Xbryk [package insert]. Incheon, South Korea: Samsung Bioepis; February 2025.
10. Xtrenbo [package insert]. Cherry Hill, NJ: Hikma Pharmaceuticals USA Inc.; September 2025.
11. The NCCN Drugs & Biologics Compendium™ © 2025 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed December 8, 2025.
12. Hu M, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144-3152.
13. El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507-528.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 18, 2026